4.7 Review

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

期刊

JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 9, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s13045-016-0265-2

关键词

Unmanipulated haploidentical stem cell transplantation; Donor; Donor-specific anti-human leukocyte antigen antibody; Natural killer alloreactivity; Age; Non-inherited maternal antigen mismatch

资金

  1. National High Technology Research and Development Program of China (Program 863) [2013AA020401]
  2. Milstein Medical Asian American Partnership Foundation
  3. Key Program of the National Natural Science Foundation of China [81230013]
  4. Scientific Research Foundation for Capital Medicine Development [2011-4022-08]
  5. National Cancer Institute of the National Institutes of Health, USA [CA 015396]

向作者/读者索取更多资源

In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than one donor. A key issue in the haplo-SCT setting is the search for the best donor, because donor selection can significantly impact the incidences of acute and chronic graft-versus-host disease, transplant-related mortality, and relapse, in addition to overall survival. In this review, we focused on factors associated with transplant outcomes following unmanipulated haplo-SCT with anti-thymocyte globulin (ATG) or after T-cell-replete haplo-SCT with post-transplantation cyclophosphamide (PT/Cy). We summarized the effects of the primary factors, including donor-specific antibodies against human leukocyte antigens (HLA); donor age and gender; killer immunoglobulin-like receptor-ligand mismatches; and non-inherited maternal antigen mismatches. We also offered some expert recommendations and proposed an algorithm for selecting donors for unmanipulated haplo-SCT with ATG and for T-cell-replete haplo-SCT with PT/Cy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据